MISEMER
GenericsMISEMER is a generic drug manufacturer focused on Immunology, Gastroenterology.
MISEMER's Key Drugs
MISEMER's core commercial portfolio centers on CHLORDIAZEPOXIDE HYDROCHLORIDE AND CLIDINIUM BROMIDE, spanning Immunology and Gastroenterology — its most strategically important drugs approved in the last 15 years.
MISEMER's Recent FDA Approvals
New NDA/BLA approvals for MISEMER over the last two years — novel drugs only, excluding generics and label supplements.
MISEMER's Therapeutic Areas
MISEMER's approved drugs and pipeline span 2 therapeutic areas, led by Immunology and Gastroenterology, across 0 biologic and 0 small-molecule drugs. Weighted by commercial stage — approved drugs count most, then late-stage trials.
MISEMER's Top Competitors
MISEMER's closest competitors by therapeutic-area and drug-target overlap include Johnson & Johnson, Bristol-Myers Squibb, and BAUSCH. Ranked by overlap in therapeutic areas and drug targets across approved drugs and pipeline.
MISEMER Pipeline Snapshot
Active clinical trials for MISEMER across all therapeutic areas, from ClinicalTrials.gov.
Pro Intelligence Preview
Deep insights for investors and analysts
Revenue Insights
- • CHLORDIAZEPOXIDE HYDROCHLORIDE AND CLIDINIUM BROMIDE leads revenue
- • Drug-level revenue analysis
Trial Catalysts
- • Immunology pipeline focus
- • Phase 3 readout tracking
Patent Risk
- • Patent expiration timeline
- • Revenue at risk analysis
Compare Companies
- • Side-by-side pipeline analysis
- • Revenue & market share comparison
Revenue forecasts • Trial milestones • Patent risk modeling
Discontinued (0)
Company Info
- First Approval
- 1993-01-29
- Latest
- 2024-11-22
- Applications
- 3